Merus N.V. (MRUS)
After hours:
| Previous close | 28.53 |
| Open | 28.54 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's range | 24.69 - 26.33 |
| 52-week range | 15.68 - 33.00 |
| Volume | |
| Avg. volume | 525,691 |
| Market cap | 997.473M |
| Beta (5Y monthly) | 0.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.55 |
| Earnings date | 03 Nov 2021 - 08 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.63 |
- Globe Newswire
Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual). The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am
- Simply Wall St.
Could The Merus N.V. (NASDAQ:MRUS) Ownership Structure Tell Us Something Useful?
If you want to know who really controls Merus N.V. ( NASDAQ:MRUS ), then you'll have to look at the makeup of its share...
- Globe Newswire
Merus Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up
